HCPLive Network
PERSONAL FINANCE

US Equity Investors Ignore Warnings

Michael Mackenzie and Vivianne Rodrigues | Tuesday, April 01, 2014
Source: Financial Times
 
As US equity investors bid adieu to the weakest first quarter in 5 years, few are dwelling on the lackluster performance.
 
Indeed, many appear to be ignoring any warning signs about the economy’s prospects: a disappointing 0.5% gain on S&P 500 in the first 3 months, set against the strong performance of long-dated bonds since January. More than ever, with the equity market bull run in its sixth year, there is optimism that stocks will enjoy further gains.
 
The bull case for equities largely comes down to 3 factors. These are expectations of a stronger economy later this year, monetary policy remaining highly supportive; while the return of retail investors is only in its early stages.
 
Such thinking by investors means disappointing data and a sharp reduction in first-quarter earnings growth estimates for S&P 500 companies is being played down, while the recent turbulence in biotechnology and internet stocks is not seen as a sign of brewing trouble, rather a healthy correction.
 
Carmine Grigoli, chief investment strategist at Mizuho Securities, expects the S&P 500 will reach 2,075 by late summer on the back of stronger profit growth. 
 
“The crucial issue for the stock market is whether we see the economy accelerate during the second half,” he says. For now, both bond and equity investors are in a state of suspense until May, when they can gauge whether the tone of data for April confirms a rebound in activity after the harsh US winter.
 
“The first quarter [for the economy] is clearly a write-off. We need to wait until we see April’s data,” says Andrew Milligan, head of global strategy at Standard Life Investments.
 
Before the widely expected spring rebound, there is the matter of the first-quarter earnings season in the coming weeks. Expectations are grim.
 
Analysts have cut sharply their expectations for S&P 500 earnings growth since January to minus 0.4% from a year-on-year rise of 4.4%, according to FactSet. Yet, they see first-quarter revenues expanding 2.5%, so the contraction in earnings suggests companies are facing higher costs.
 


RELATED ARTICLES
With the pressures of the holidays, a growing probability of going over the fiscal cliff and weak job security, a good New Year’s resolution for many might be to schedule a stress test for your portfolio.
Adding private equity funds to your portfolio can lead to higher returns and lower risk over the long term, but choosing a private fund takes much more due diligence than selecting a mutual fund.
The truth is you don’t have to take big risks to make a lot of money in the market. You only have to know what you’re doing… Otherwise you'll learn some painful and hideously expensive lessons.
RECENT CLINICAL ARTICLES
Patients newly diagnosed with diabetes have an increased risk of developing head and neck cancer, according to a study published online July 24 in JAMA Otolaryngology-Head & Neck Surgery.
Abuse-deterrent properties, identical efficacy for pain relief, reversal of opioid-induced constipation, and theoretical tolerance mitigation may give Targiniq ER an interesting advantage over other oral opioids.
Most parents want the doctor to answer their questions about circumcision, but they do not want a specific recommendation for their baby, according to a report published July 21 by the C.S. Mott Children's Hospital.